TY - JOUR
T1 - Fatty acid composition in the postmortem amygdala of patients with schizophrenia, bipolar disorder, and major depressive disorder
AU - Hamazaki, Kei
AU - Hamazaki, Tomohito
AU - Inadera, Hidekuni
N1 - Funding Information:
K.H. received research support from the Japan Society for the Promotion of Science, the Tamura Foundation for Promotion of Science and Technology, and the Ichiro Kanehara Foundation for Promotion of Medical Sciences and Medical Care, and consultancy fees from Polyene Project, Inc. and Otsuka Pharmaceutical Co., Ltd., as well as lecture fees and research support from Nippon Suisan Kaisha, Ltd. T.H. has received research support from the Japan Society for the Promotion of Science, Open Research Center for Lipid Nutrition (Kinjo Gakuin University), and Nippon Suisan Kaisha, Ltd., consultancy fees from Polyene Project, Inc. and Otsuka Pharmaceutical Co., Ltd., and lecture fees from Mochida Pharmaceutical Co., Ltd.
Funding Information:
This work was supported by the Japan Society for the Promotion of Science , the Ichiro Kanehara Foundation for Promotion of Medical Sciences and Medical Care , and Polyene Project, Inc . The funding sources had no further role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.
PY - 2012/8
Y1 - 2012/8
N2 - Previous studies with postmortem brain tissues showed abnormalities in n-3 polyunsaturated fatty acids (PUFAs) in the orbitofrontal cortex of individuals with schizophrenia and mood disorders. However, in the hippocampus, we were not able to find any significant differences in PUFAs except for small differences in n-6 PUFAs. In the present study we investigated levels of PUFAs in the amygdala of postmortem brains from patients with schizophrenia, bipolar disorder, and major depressive disorder (MDD) compared with those of unaffected controls. Amygdala samples from patients with schizophrenia (n = 15), bipolar disorder (n = 15), or MDD (n = 15), and controls matched for age, sex, and five other confounding factors (n = 15) were analyzed for fatty acid composition by gas chromatography. In contrast to previous studies of the orbitofrontal cortex and hippocampus, we were unable to find any significant differences in major PUFAs. The relative compositions of docosahexaenoic acid (DHA), the major n-3 PUFA, were 10.0 ± 1.1%, 10.0 ± 1.3%, 9.3 ± 1.3%, and 9.7 ± 1.1%, respectively, in patients with schizophrenia, bipolar disorder, and MDD and unaffected controls (not significantly different). The corresponding relative compositions of arachidonic acid (AA), the major n-6 PUFA, were 9.0 ± 0.8%, 9.2 ± 0.5%, 9.4 ± 0.7%, and 9.4 ± 0.7%, respectively (not significantly different). Significant differences were found in some of the other fatty acids. In particular, we found a 6.5% increase in palmitic acid and 6.2% decrease in oleic acid in patients with MDD compared to controls. With regard to schizophrenia, there was an 8.0% decrease in docosatetraenoic acid compared to controls. In conclusion, the changes in DHA and/or AA seen in orbitofrontal cortex and hippocampus were not observed in amygdala. These changes may be specific to particular brain regions.
AB - Previous studies with postmortem brain tissues showed abnormalities in n-3 polyunsaturated fatty acids (PUFAs) in the orbitofrontal cortex of individuals with schizophrenia and mood disorders. However, in the hippocampus, we were not able to find any significant differences in PUFAs except for small differences in n-6 PUFAs. In the present study we investigated levels of PUFAs in the amygdala of postmortem brains from patients with schizophrenia, bipolar disorder, and major depressive disorder (MDD) compared with those of unaffected controls. Amygdala samples from patients with schizophrenia (n = 15), bipolar disorder (n = 15), or MDD (n = 15), and controls matched for age, sex, and five other confounding factors (n = 15) were analyzed for fatty acid composition by gas chromatography. In contrast to previous studies of the orbitofrontal cortex and hippocampus, we were unable to find any significant differences in major PUFAs. The relative compositions of docosahexaenoic acid (DHA), the major n-3 PUFA, were 10.0 ± 1.1%, 10.0 ± 1.3%, 9.3 ± 1.3%, and 9.7 ± 1.1%, respectively, in patients with schizophrenia, bipolar disorder, and MDD and unaffected controls (not significantly different). The corresponding relative compositions of arachidonic acid (AA), the major n-6 PUFA, were 9.0 ± 0.8%, 9.2 ± 0.5%, 9.4 ± 0.7%, and 9.4 ± 0.7%, respectively (not significantly different). Significant differences were found in some of the other fatty acids. In particular, we found a 6.5% increase in palmitic acid and 6.2% decrease in oleic acid in patients with MDD compared to controls. With regard to schizophrenia, there was an 8.0% decrease in docosatetraenoic acid compared to controls. In conclusion, the changes in DHA and/or AA seen in orbitofrontal cortex and hippocampus were not observed in amygdala. These changes may be specific to particular brain regions.
KW - AA
KW - Bipolar disorder
KW - Case-control study
KW - DHA
KW - DPA
KW - MDD
KW - Major depressive disorder
KW - PUFAs
KW - Polyunsaturated fatty acids
KW - Postmortem brain
KW - SMRI
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=84863483992&partnerID=8YFLogxK
U2 - 10.1016/j.jpsychires.2012.04.012
DO - 10.1016/j.jpsychires.2012.04.012
M3 - 学術論文
C2 - 22572570
AN - SCOPUS:84863483992
SN - 0022-3956
VL - 46
SP - 1024
EP - 1028
JO - Journal of Psychiatric Research
JF - Journal of Psychiatric Research
IS - 8
ER -